Please login to the form below

Not currently logged in
Email:
Password:

Idera

This page shows the latest Idera news and features for those working in and with pharma, biotech and healthcare.

Big pharma and biotech M&A activity increases in Q4 2006

530. Idera. Merck. Toll-like Receptor (TLR) agonists. 455. AC Immune. Genentech.

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    There are various companies working on toll-like receptor agonists that stimulate antigen-presenting cells, such as Idera’s TLR9-targeted drug IMO-2125 which boosted the activity of BMS’CTLA4

  • Deal Watch November 2016 Deal Watch November 2016

    acquisition - company. 235. Idera Pharmaceuticals/ Vivelix Pharmaceuticals. IMO-9200, antagonist of TLR 7, 8 and 9, for non-malignant GI disorders (p1) back ups.

  • Deal Watch November 2015 Deal Watch November 2015

    Option to license. 175. Idera Pharmaceuticals. GlaxoSmithKline. Licence, collaboration. Antisence platform for selected targets in renal disease.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • ImmuneXcite boosts senior leadership ImmuneXcite boosts senior leadership

    He is chairman of the board of Idera Pharmaceuticals and Juniper Pharmaceuticals and has previously worked at Sanofi-Aventis and Genzyme.

  • Idera Pharmaceuticals names new CEO Idera Pharmaceuticals names new CEO

    Idera Pharmaceuticals names new CEO. Vincent Milano was most recently CEO of Viropharma. ... Vincent Milano has been appointed CEO of Idera Pharmaceuticals almost one year after stepping down as CEO of ViroPharma.

  • Former Sanofi SVP to chair Idera Former Sanofi SVP to chair Idera

    Former Sanofi SVP to chair Idera. James Geraghty joins the firm with 20 years biotech experience from Genzyme. ... Idera specialises in developing toll-like receptors (TLRs) for autoimmune and inflammatory conditions and will benefit from Geraghty's

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

A reflection of ESMO
Client Relationship Director Fabienne Wild from Ashfield Meetings & Events reflects on the recent conference season and on her experience at the European Society for Medical Oncology (ESMO)....
OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....

Infographics